Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345421 · ClinicalTrials.gov registry record
A Study to Identify and Characterize LAL-D Patients in High-risk Populations
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- 640
- Enrollment target
NCT02345421: Clinical Trial study, sponsored by Alexion Pharmaceuticals.
NCT02345421 is a clinical trial that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 640 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02345421 was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- 640 participants
- Enrollment target
Study Summary
The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.
Primary Outcome
The endpoint of this study is the frequency of LAL D in at-risk patients, based on results from the LAL enzyme assay.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-10 |
Why NCT02345421 stopped before completion
NCT02345421 is an observational study that tracks outcomes without assigning an intervention. The registered 640 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02345421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02345421 about?
NCT02345421 is a clinical study titled "A Study to Identify and Characterize LAL-D Patients in High-risk Populations". The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.
What is the current status of trial NCT02345421?
This trial is currently terminated. The enrollment target is 640 participants. The study started on 2014-12. Estimated completion is 2015-10.
Who is sponsoring clinical trial NCT02345421?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
- NCT05156398 · 640 participants · Phase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- NCT05930483 · 640 participants · NA
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia